These results suggest that the AD-specific increases in CSF p-tau biomarkers might be a by-product of the overall increase in amounts of phosphorylated tau protein in AD rather than actual disease specificity per se of a given amino acid residue, as non-AD pathologies do also display increased levels of p-tau residues in brain, but to a much lesser degree than AD. Here, MAPT is linked to Alzheimer disease.